Author:
Lin Yi-Hsuan,Kuo Nai-Rong,Shen Hsiao-Chin,Chang Yun-Chien,Lin Roger,Liao Tsai-Ling,Yeh Hsiao-Yun,Yang Ying-Ying,Hou Ming-Chih,Lin Han-Chieh
Abstract
AbstractThe development of acute kidney injury (AKI) and hepatorenal syndrome–acute kidney injury (HRS–AKI) in cirrhosis has been associated with intestinal barrier dysfunction and gut-kidney crosstalk. We use the related markers such as zonulin, lipopolysaccharides (LPS), and lipopolysaccharide-binding protein (LBP) to predict AKI and HRS–AKI in cirrhotic patients and evaluate their in vitro effects on intestinal (Caco-2) cells and renal tubular (HK-2) cells. From 2013 to 2020, we enrolled 70 cirrhotic patients and developed prediction models for AKI and HRS–AKI over a six-month period. There were 13 (18.6%) and 8 (11.4%) cirrhotic patients developed AKI and HRS–AKI. The prediction models incorporated zonulin, LPS, LBP, C-reactive protein, age, and history of hepatitis B for AKI, and zonulin, LPS, LBP, total bilirubin, and Child–Pugh score for HRS–AKI. The area under curve (AUC) for the prediction of AKI and HRS–AKI was 0.94 and 0.95, respectively. Furthermore, the conditioned medium of LPS+hrLBP pre-treated Caco-2 cells induced apoptosis, necrosis, and zonulin release in HK-2 cells, demonstrating the communication between them. This study found that zonulin, LPS, and LBP are potential practical markers for predicting AKI and HRS–AKI in cirrhotic patients, which may serve as potential targets for renal outcomes in cirrhotic patients.
Funder
Taipei Veterans General Hospital
Hsinchu Science Park Bureau, Ministry of Science and Technology, Taiwan
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. du Cheyron, D., Bouchet, B., Parienti, J. J., Ramakers, M. & Charbonneau, P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med. 31, 1693–1699 (2005).
2. Tariq, R. et al. Incidence, mortality and predictors of acute kidney injury in patients with cirrhosis: A systematic review and meta-analysis. J. Clin. Transl. Hepatol. 8, 135–142 (2020).
3. Cardenas, A. & Arroyo, V. Hepatorenal syndrome. Ann. Hepatol. 2, 23–29 (2003).
4. Flamm, S. L. et al. The current management of hepatorenal syndrome-acute kidney injury in the United States and the potential of terlipressin. Liver Transpl. 27, 1191–1202 (2021).
5. Abarca Rozas, B., Mestas Rodríguez, M., Widerström Isea, J., Lobos Pareja, B. & Vargas Urra, J. A current view on the early diagnosis and treatment of acute kidney failure. Medwave 20, e7928 (2020).